NewAmsterdam Pharma (NAMS) Operating Margin (2023 - 2025)
Historic Operating Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 15845.69%.
- NewAmsterdam Pharma's Operating Margin fell 157598000.0% to 15845.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 575.81%, marking a year-over-year decrease of 276900.0%. This contributed to the annual value of 386.91% for FY2024, which is 9116500.0% up from last year.
- According to the latest figures from Q3 2025, NewAmsterdam Pharma's Operating Margin is 15845.69%, which was down 157598000.0% from 186.13% recorded in Q2 2025.
- NewAmsterdam Pharma's 5-year Operating Margin high stood at 85.89% for Q3 2024, and its period low was 15845.69% during Q3 2025.
- Its 3-year average for Operating Margin is 3274.48%, with a median of 2306.93% in 2024.
- As far as peak fluctuations go, NewAmsterdam Pharma's Operating Margin skyrocketed by 60219300bps in 2024, and later plummeted by -157598000bps in 2025.
- NewAmsterdam Pharma's Operating Margin (Quarter) stood at 6360.4% in 2023, then soared by 95bps to 338.47% in 2024, then crashed by -4582bps to 15845.69% in 2025.
- Its Operating Margin stands at 15845.69% for Q3 2025, versus 186.13% for Q2 2025 and 2314.47% for Q1 2025.